Therapeutic perspectives in HIV-1 infection from recent advances in HIV-1 pathogenesis: It is time to move on

Journal of Biological Regulators and Homeostatic Agents

Volumn 13, Issue 3, 1999, Pages 151-157

  Rizzardi, G P ^a   Pantaleo, G ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

HAART; HIV 1 infection; Immune based strategies; Pathogenesis

Indexed keywords

2',3' DIDEOXY 2' FLUOROADENOSINE; 3 ETHYL 6 FLUORO 4 ISOPROPOXYCARBONYL 3,4 DIHYDRO QUINOXALIN 2(1H) ONE; ABACAVIR; ADEFOVIR DIPIVOXIL; AG 1776; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; DMP 961; DMP 963; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PHTHALIC ACID DIMETHYL ESTER; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; ERADICATION THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; INFECTION CONTROL; NONHUMAN; PATHOGENICITY; SURVIVAL;

EID: 0033303222     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. HIV-1 protease inhibitors. A review for clinicians
2. Treatment with indinavir zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team
4. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
5. Caution: Should we be treating HIV infection early?
6. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
7. + T cells in blood and lymphnodes of HIV-1-infected therapy naive adults at early stage of chronic infection treated with abacavir plus amprenavir
8. A phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (E-FV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 48 weeks
9. HIV-protease inhibitors
10. Severe hepatitis in three AIDS patients treated with indinavir
11. Crystalluria and urinary tract abnormalities associated with indinavir
12. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
13. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy
14. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
15. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy
16. Decay characteristics of HIV-1-infected compartments during combination therapy
17. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary infection
18. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
19. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
20. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV- 1-infected individuals
21. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
22. In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency
23. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
24. + T cells during primary HIV-1 infection
25. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
26. Quantifying residual HIV-1 replication and decay of the latent reservoir in patients on seemingly effective combination antiretroviral therapy
27. Viral dynamics in HIV-1 infection
28. Detection of low HIV-1 RNA levels in plasma
29. Can HIV be eradicated?
30. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
31. Ziagen/Combivir is equivalent to indinavir/Combivir in antiretroviral therapy (ART) naive adults at 24 weeks (CNA3005)
32. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
33. + T cell homeostasis and function in advanced HIV disease
34. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir
35. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study
36. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
37. + lymphocytes during antiretroviral therapy
38. Impact of HAART on the diversity of the TCR β chain repertoire and the persistence of HIV-specific CTL responses during and following primary HIV infection
39. Antiretroviral therapy for HIV infection: Promises and problems
40. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
41. + T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy
42. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale sur le SIDA 072) Study Team
43. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team
44. How immune-based interventions can change HIV therapy
45. Strategies for immune restoration